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obtain ICERs of HMG-CoA Reductase Inhibitors com-
pared to aspirin.
RESULTS: The base-case results of the model show 
that the highest ICER in males is $2,932/QALY, and for
females is $5,441/QALY. One-way sensitivity analyses
show the variable with the highest variance in cost/QALY
results in an ICER of $12,252/QALY. Secondary analysis
shows the ICERs for males and females using HMG-CoA
Reductase Inhibitors compared to aspirin are under
$26,000/QALY for all ages. 
CONCLUSION: This research study shows that the use
of prophylaxis aspirin (75mg/day) is cost-effective for the
primary prevention of CVD in males and females aged
40–80. The use of HMG-CoA Reductase Inhibitors com-
pared to aspirin provides higher effectiveness but at
higher costs, resulting in ICERs up to $26,000/QALY.
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OBJECTIVES: To estimate the incremental cost-
effectiveness ratios (ICER) of statin monotherapy for
attaining NCEP ATP II LDL-cholesterol (LDL-C) goal
levels from a managed care organization (MCO) 
perspective. 
METHODS: Total and dyslipidemia attributable costs of
care (medication, physician ofﬁce visits, laboratory) and
consequences (resource use associated with atheroscle-
rotic vascular events) were captured between 1/98 and
12/00 for patients newly started on statin therapy from a
southeast US MCO. Costs (year 2000 $US) were con-
verted using an inﬂation adjusted discount rate. Follow-
up costs and probabilities of attaining LDL-C goal were
estimated using multivariable OLS and logistic regression,
respectively. Costs were log transformed prior to regres-
sion. Covariates were selected based on ﬁt and clinical
relevance, and included baseline total costs, age, gender,
cogent clinical subgroups, and duration of follow-up.
Mean differences in all pair-wise ICER were evaluated by
applying non-parametric bootstrap techniques.
RESULTS: A total of 1,651 patients were captured and
followed for a median duration of 19.4 months. Fluvas-
tatin, pravastatin, atorvastatin, and simvastatin adjusted
mean attributable costs and respective adjusted probabil-
ities of obtaining goal were $1,354 (0.51), $2,320 (0.57),
$2,451 (0.75), $2,964 (0.7), respectively. In the base case
analysis, the mean [95%CI] attributable cost per LDL-C
goal obtained vs. no therapy was: ﬂuvastatin: $2,654
[$828–$4,878], atorvastatin: $3,268 [$1,009–$5,994],
pravastatin: $4,070 [$1,269–$7,800], simvastatin:
$4,234 [$1,327–$7,818]. The ICER to obtain one addi-
tional goal for atorvastatin, simvastatin, and pravastatin
as compared to ﬂuvastatin was $4,570 [$1,349–$9,664],
$8,473 [$2,537–$19,558], $16,100 [$3,537-NW],
respectively. The ICER of atorvastatin dominated sim-
vastatin (simvastatin higher mean [95%CI] cost and
lower mean [95%CI] probability of obtaining goal). The
results were not sensitive to changes in inﬂation rate or
model selection.
CONCLUSIONS: This analysis suggests atorvastatin has
a reasonable incremental cost per goal attained as com-
pared to ﬂuvastatin, pravastatin, and simvastatin in this
population. Atorvastatin, compared to simvastatin, pro-
vided more effect for less cost.
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While ﬁbrates are clinically recommended for patients
with low HDL cholesterol, the pharmacoeconomic liter-
ature on U.S. FDA-approved ﬁbrates (gemﬁbrozil and
fenoﬁbrate) is limited.
OBJECTIVES: To determine the cost-effectiveness of 
the ﬁbrates in the primary prevention of CHD events in
patients with low-levels of HDL (<35mg/dl) from the
societal perspective. 
METHODS: An economic model was created utilizing a
hypothetical cohort of United States males and females
aged 45–79, with low levels of HDL, and no history of
CHD. The source of data for predicted probabilities, the
expected mortality rates, CHD event related treatment
costs (in year 2000 dollars) is from the literature includ-
ing the VA-HIT study; and the model utilized a discount
rate of 3% and a lifetime time horizon. A sensitivity
analysis was performed to determine the robustness of the
model.
RESULTS: In the base case scenario, males are more 
cost-effective than females for both gemﬁbrozil and
fenoﬁbrate. For males, as age increases the ratios of cost-
effectiveness in terms of cost per life year gained decreases
($31,286–$4,930 for gemﬁbrozil; $43,750– $8,991 for
fenoﬁbrate). In terms of cost per QALY, the ratios of cost-
effectiveness decreases with age in addition to a slight
increase at age 75 ($8,119–$4,641 for gemﬁbrozil;
$11,354–$8,464 for fenoﬁbrate). For females, the cost
per life year gained ratios decrease with age with a slight
increase at age 70 ($43,750–$8,991 for gemﬁbrozil;
$56,999–$30,789 for fenoﬁbrate). In contrast, the cost
per QALY ratios of cost-effectiveness increases with age
with higher ratios at age 75 than at age 45 ($15,371–
$20,489 for gemﬁbrozil; $21,619–$28,425 for fenoﬁ-
brate). The results of the sensitivity analysis were consis-
tent with the results of the base case scenario. 
CONCLUSION: This economic model demonstrates that
treating men with ﬁbrates are more cost-effective than
treating women at any age, and all cost-effectiveness
ratios are less than a $50,000 threshold, except for 45
year-old women treated with fenoﬁbrate.
